Biocon Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Biocon Announces U.S. Commercial Launch of Bosaya and Aukelso , Denosumab Biosimilars".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Limited has commercially launched Bosaya™ and Aukelso™ (denosumab biosimilars) in the United States. Bosaya™ is a biosimilar to Prolia® for osteoporosis treatment, while Aukelso™ is a biosimilar to Xgeva® for bone complications from cancer. Both products received U.S. FDA approval in September 2025 with interchangeable designation, enabling automatic pharmacy-level substitution. The U.S. denosumab market generated approximately $5 billion in sales in 2024. These products target an estimated 10 million U.S. adults with osteoporosis and over 330,000 cancer patients with bone metastasis annually. The launch represents a strategic expansion of Biocon's biosimilars portfolio in oncology and immunology.
Positive for shareholders as this launch diversifies Biocon's U.S. revenue stream and leverages its existing biosimilars infrastructure. The interchangeable designation gives these products a competitive edge over non-interchangeable biosimilars.